CLINICAL TRIALS PROFILE FOR FLUOROESTRADIOL F-18
✉ Email this page to a colleague
All Clinical Trials for FLUOROESTRADIOL F-18
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01153672 ↗ | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | Completed | National Cancer Institute (NCI) | N/A | 2010-11-01 | This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug |
NCT01153672 ↗ | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | Completed | University of Washington | N/A | 2010-11-01 | This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug |
NCT01627704 ↗ | Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer | Completed | Assistance Publique - Hôpitaux de Paris | N/A | 2012-06-01 | Compare the response rate after 6 months of hormone treatment (or a major change in hormone treatment) in metastatic breast cancer, according to the uptake of FES in metastatic lesions taking-up FDG on PET/CT at baseline. Hypothesis: best response rate will be observed in patients with all metastases taking up FES prior to treatment. |
NCT01714128 ↗ | FES-PET for Patients Treated on NCI Protocol 8762 | Withdrawn | Washington University School of Medicine | N/A | 2013-06-01 | A significant number of all invasive breast cancers are hormone sensitive and may be candidates for treatment with hormonal therapy. This project will assess the ability and usefulness of imaging hormone-receptor status in breast cancer with positron emission tomography (PET) and 6α-[18F]fluoro-17β-estradiol (FES), an estrogen analogue in patients who are scheduled to be treated with hormonal therapy given in combination with a selective allosteric inhibitor of AKT protein kinase (MK2206) . |
NCT01720602 ↗ | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | Completed | National Cancer Institute (NCI) | N/A | 2012-11-01 | This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug. |
NCT01720602 ↗ | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | Completed | University of Washington | N/A | 2012-11-01 | This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug. |
NCT01916122 ↗ | Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status | Recruiting | Memorial Sloan Kettering Cancer Center | Early Phase 1 | 2013-08-01 | These are tumors which expresses estrogen receptors. Estrogen receptors are found within breast cancer cells and are an important marker of which medicines may best treat a breast cancer. This study is being performed to imaging the amount of estrogen receptors expressed in the tumor. A research agent named 16α-18F-fluoroestradiol (FES) finds estrogen receptors and binds to them. Then tumors with estrogen receptors can be imaged by a PET/CT scanner, a machine that can take pictures of where the FES is and how much FES is present. The results of this study may help researchers know whether FES can be used to monitor changes in estrogen receptors in tumors during treatment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FLUOROESTRADIOL F-18
Condition Name
Clinical Trial Locations for FLUOROESTRADIOL F-18
Trials by Country
Clinical Trial Progress for FLUOROESTRADIOL F-18
Clinical Trial Phase
Clinical Trial Sponsors for FLUOROESTRADIOL F-18
Sponsor Name